Palisade Bio has initiated dosing in its phase 2b ASCENTRA-UC trial for its oral PDE4 inhibitor prodrug PALI-2108, targeting ulcerative colitis, with topline results expected in Q4 2027. The company also plans a phase 2a trial for Crohn's disease starting in Q1 2027, with data anticipated in Q1 2028. With $125.2 million in cash as of mid-2026, Palisade Bio is well-funded to support these trials and minimize near-term dilution risk. This development offers potential growth catalysts for investors interested in inflammatory bowel disease treatments.
Palisade Bio's cash position of $125.2 million as of mid-2026 provides a strong financial foundation for its ongoing and planned clinical trials in ulcerative colitis and Crohn's disease. For readers following the health sector, here is Pluang's market snapshot as of Nov 02, 2026 23:14 WIB: out of 150 priced US health stocks, 55 rose and 94 fell today. Notable movers include CGC at USD 0.70 with a 1-day change of +6.66%, ALMS at USD 6.30 down 6.53%, and TXG at USD 65.62 down 6.40%.
Exosens disclosed its monthly update on the total number of shares and voting rights in its share capital as of October 31, 2026. The company has 50,936,749 shares outstanding, with 59,162,039 exercisable voting rights after deducting treasury shares...
Exosens has released its monthly update on the total number of shares and voting rights composing its capital as of October 31, 2026. The company reports 50,936,749 total shares and 59,425,768 theoretical voting rights, with 59,162,039 exercisable vo...
The global wealth management software market, valued at $6.28 billion in 2025, is projected to reach $18.77 billion by 2033, growing at a 14.7% CAGR. Growth is fueled by rising adoption of AI, automation, and digital advisory tools that enhance workf...
Maurizio Mian, known as the pioneer of influencer culture, has launched a new micro-drama series called 'The Experiment.' The show features popular social media personalities living in luxury while exploring whether happiness can be measured and incr...
The global bio-based construction polymer market, valued at $18.2 billion in 2025, is projected to grow to $35 billion by 2033 at an 8.3% CAGR. Growth is fueled by rising demand for sustainable building materials that reduce greenhouse gas emissions ...
